These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 17919258)

  • 1. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
    Pacher P; Szabó C
    Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.
    Pacher P; Szabo C
    Am J Pathol; 2008 Jul; 173(1):2-13. PubMed ID: 18535182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
    Szabó C
    Curr Vasc Pharmacol; 2005 Jul; 3(3):301-3. PubMed ID: 16026326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly (ADP-ribose) polymerase activation and circulatory shock.
    Szabó C
    Novartis Found Symp; 2007; 280():92-103; discussion 103-7, 160-4. PubMed ID: 17380790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ; Szabó C
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    Curtin NJ; Szabo C
    Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
    Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
    Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
    Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
    J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock.
    Evgenov OV; Liaudet L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):293-9. PubMed ID: 16026325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
    Kiss L; Szabó C
    Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():29-37. PubMed ID: 15962096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel modulators of poly(ADP-ribose) polymerase.
    Szabo C; Pacher P; Swanson RA
    Trends Pharmacol Sci; 2006 Dec; 27(12):626-30. PubMed ID: 17055069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
    de la Lastra CA; Villegas I; Sánchez-Fidalgo S
    Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
    Komjáti K; Besson VC; Szabó C
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
    Pacher P; Liaudet L; Mabley JG; Cziráki A; Haskó G; Szabó C
    Int J Mol Med; 2006 Feb; 17(2):369-75. PubMed ID: 16391839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.